Introduction
In the past years there has been increasing evidence that lymphocytes can recognize tumor-associated antigens (TAA) in humans. 1, 2 Small peptide fragments of 8-12 amino acid lengths can bind to the peptide-binding region of MHC class I molecules. These MHC-peptide complexes can then be recognized by CD8 + T cells. The lack of reactivity against such TAA in vivo can be explained by different mechanisms: down-regulation of MHC class I molecules; 3, 4 defects in the machinery that transports peptides from the cytoplasm to the endoplasmatic reticulum; 5 local secretion of inhibitory factors and cytokines; 6 and lack of expression of accessory molecules on the surface of the tumor cells. 7 For activation of cytotoxic T cells it is necessary that the cell presenting the TAA expresses accessory molecules such as CD80 (B7.1) and CD86 (B7.2). Presentation of MHC-peptide complexes to T cells in the absence of accessory molecules induces anergy rather than cytotoxic immunity. 7 Tolerance to TAA is likely to play a role in the growth of tumors in vivo. 8 Several tumor cell lines can be converted into efficient immunostimulatory cells by transfecting the genes that code for the CD80 antigen B7-1. 9, 10 A further strategy to enhance immunoreactivity against a TAA relies on loading professional antigen presenting cells with TAA. Methods for the generation of large amounts of dendritic cells (DC) in vitro from CD34 + bone marrow progenitor cells 11 or from peripheral blood mononuclear cells 12, 13 have been described. Presentation of foreign antigens on the surface of DC can be achieved by antigen (peptide) pulsing. [14] [15] [16] [17] [18] [19] [20] According to recent observations, 21 exogenous peptides can enter the MHC class I pathway of antigen presentation and induce cytotoxic T cell responses. Alternatively, presentation of TAA in APC can be achieved by gene transfer techniques. 22 We have previously demonstrated that genes coding for foreign antigens can be efficiently transduced into dendritic cells using retroviral vectors. 23 Retroviral transduction of genes coding for TAA in CD34-derived DC has been reported for MUC1 and MART1. 24, 25 In this article we describe the modification of DC with a vector that codes for human interleukin-7 (IL-7). IL-7 is a stromal cell-derived cytokine which stimulates the growth of pre-B cells, immature 26, 27 and mature T cells. [28] [29] [30] Immunotherapeutic approaches in animal models have suggested a potential role for IL-7 in immunotherapy. [31] [32] [33] Several gene therapy protocols are currently under evaluation, in which tumor cells have been genetically engineered to secrete cytokines (IL-2, IL-4, ␥-interferon, TNF-␣, GM-CSF and others 34 ). In animal models these tumor cells have vaccine efficiency, showing that stimulation of T cells may induce tumor immunity. We asked whether the expression of IL-7 in DC is capable of augmenting stimulation of T cells which might eventually be useful in response to TAA.
Results
In vitro generation of DC DC were generated by cultivation of T and B celldepleted PBMC in the presence of GM-CSF and IL-4 for 6-7 days. Typically, 75-85% of the nonadherent cells showed cytoplasmic processes, typical of DC (Figure 1 ). Electron microscopy ( Figure 2 ) revealed features of DC: 12 cytoplasmic extensions devoid of organelles, a marked accumulation of mitochondria within the cytoplasm and a paucity of lysosomes. Immunophenotypic analysis by FACS ( Figure 3) showed a lack or low numbers of CD3-, CD19-and CD14-positive cells. Of the cells used in the experiments 70-85% were positive for CD1a and more than 90% expressed high levels of HLA-DR. Furthermore, the cells expressed high levels of CD80 and CD4 ( Figure 3 ) as well as CD86, CD40 and CD54 (not shown). In allogeneic MLR, T cell proliferation induced by DC was up to 30-fold higher as compared with PBMC or non-T cells (data not shown 23 ). Viability of the cells was always higher than 90% according to trypan blue staining technique.
As analyzed by direct immunofluorescence using PEconjugated anti-IL-7 receptor antibody, unmodified DC as well as IL-7 and mock-transfected DC did not express the IL-7 receptor (Figure 3) . Cultures of unmodified and mock-transfected DC did not contain measurable amounts of IL-7 as determined by ELISA (see Table 1 ).
Retroviral IL-7 gene transfer in DC
After retroviral transfection with the vectors LXSNhIL-7 or LXSN (mock) as described above, quantification of IL-7 production was performed on day 7 of the cell (Table 1) . Cell viability on day 1 of culture was always Ͼ90% according to trypan blue staining technique, proliferative activity as judged by cell density in the culture flasks during the first days varied between the different donor PBMC preparations. For efficient gene transfer it was essential to start retroviral infection cycles on day 1 or 2, since proliferative activity of the cells decreased progressively during culture. IL-7 was reproducibly transduced into DC and was secreted in substantial amounts. Table  1 shows the data from several independent experiments.
In order to confirm gene transfer into DC, mRNA coding for neomycin phosphotransferase (NPT) was amplified by RT-PCR. NPT-mRNA was detected in the cell cultures which were infected with retroviral supernatant and produced IL-7 ( Figure 4 ). To be certain that DC were transduced, RT-PCR for NPT-mRNA was performed after immunomagnetic separation of CD1a-positive cells. Figure 5 shows detection of NPT-mRNA by RT-PCR in this CD1a-enriched cell fraction.
To estimate transduction efficiency with this protocol, a control retrovirus coding for ␤-galactosidase having a similar virus titer, was used. In this case, staining allows precise quantification of transfected cells. In three consecutive experiments, transduction efficiency was 28 ± 5% (data not shown 23 ).
Furthermore, we could demonstrate in three consecutive experiments that early retroviral infection cycles are 
Figure 5 RT-PCR for neomycin phosphotransferase in a CD1a-enriched DC-fraction. RT-PCR for neomycin phosphotransferase (NPT) in a DC culture after retroviral transduction with LXSN-hIL-7 and immuno-magnetic separation into a CD1a
+ and a CD1a − cell fraction. essential for transduction efficiency. Using four infection cycles on days 1, 2, 3 and 5, transduction efficiency was about 30% (23%, 33%, 28%). With one single infection cycle on culture day 5, no substantial gene transfer could be achieved (transduction efficiency Ͻ5% or 0%, respectively).
IL-7 transduced DC amplify T cell proliferation DC were cultured in FCS. Since APC show a high antigen uptake and T cell stimulation capacity, autologous MLR may allow T cell proliferation against foreign components of the FCS. 35 In autologous MLR with 10% FCS as a source of xenogenic antigen, IL-7 transduced DC showed a two-fold stronger stimulatory capacity when compared with mock-transfected or nontransfected DC preparations. Figure 6a shows one of four representative experiments performed.
In allogeneic MLR, T cell stimulation could be amplified by a factor of 2.7 using IL-7 transduced DC. One of four representative experiments is demonstrated in Figure 6b .
In order to exclude the possibility that the changes induced by IL-7 on T cell proliferation were mediated by indirect effects on the function of DC (eg by signaling through shared cytokine receptor chains), the influence of exogenously supplied IL-7 on DC function was evaluated. IL-7 was added to DC cultures at different concentrations (2 and 20 ng/ml) in two consecutive experiments. On day 6 of the culture, DC were extensively washed and tested in allogeneic MLR. Comparing DC cultured in the standard cytokine mixture of GM-CSF and IL-4 with DC cultured in the presence of GM-CSF, IL-4 and IL-7 we observed no differences in the ability to stimulate T cell proliferation. In one of the experiments 3 H-thymidine incorporation was 36 092 c.p.m. for standard DC, 32 771 c.p.m. for DC cultured in 2 ng/ml IL-7 and 32 854 c.p.m. for DC cultured in 20 ng/ml IL-7 (data at stimulator:responder ratio of 1:10, comparable c.p.m. rates were observed over the whole range of stimulator:responder ratios).
Figure 6 IL-7 transduced DC amplify T-cell proliferation in autologous (a) and allogeneic (b) MLR. IL-7 secretion of DC in the autologous
To confirm further the increased T cell stimulatory ability of IL-7 transduced DC, secretion of tumor necrosis factor alpha (TNF-␣), a cytokine that is secreted both by CD4 + and CD8 + T cells, was evaluated. The concentration of TNF-␣ was measured by ELISA in the supernatant of a coculture of 10 4 IL-7 or mock-transduced DC with 10 5 allogeneic T cells in 0.2 ml medium. TNF-␣ and IL-7 concentrations were determined simultaneously in the single culture wells. In two experiments, substantial amounts of IL-7 were secreted by IL-7 transduced DC (100 and 125 pg/ml). The TNF concentrations were up to four-fold higher in the wells with IL-7 transduced DC (480 and 520 pg/ml, respectively) as compared with mocktransfected DC (120 and 160 pg/ml, respectively). Maximum TNF release was 600 and 640 pg/ml for T cells cultured in the presence of 1 g/ml PHA and 75 and 85 pg/ml, respectively for unstimulated T cells alone. It is remarkable that in both the autologous and allogeneic MLR the stimulatory ability of IL-7 transduced DC was improved at different stimulator:responder ratios. With cultures containing 10 4 
In order to determine the amount of IL-7 which is produced by DC in the MLR assay, the cytokine concentration was determined in the wells of 96-well plates in which the MLR were performed. In the wells with 10 4 DC/0.2 ml as stimulator cells, 78 pg/ml IL-7 were measured by ELISA after 24 h of culture. This can be extrapolated to an IL-7 production of 1560 pg/10 6 cells/24 h. After 48 h, 100 pg/ml IL-7 were measured in the same wells, corresponding to 2000 pg/10 6 cells.
Discussion
In this article we have demonstrated that DC that have been gene-modified to secrete IL-7, have improved T cell stimulatory capacity. We have previously shown that dendritic cells can be efficiently modified by retroviral vectors using ␤-galactosidase as a reporter gene. 23 Dendritic cells are considered to be crucial for the priming of naive T cells. 15, 36 Application of tumor antigen-pulsed DC has been validated both in vitro and in animal models as an approach for induction of protective antitumor immunity. In these experiments, ex vivo generated DC loaded with tumor-associated peptides, can mediate protective immunity against a consecutive tumor challenge 18, 19 and against small tumor loads. 20, 37 In mouse models, DC were less efficient in the case of weakly immunogenic tumors compared with tumors with high immunogenicity. 37 The aim of our work was to augment T cell stimulatory capacity of DC by transduction of the T cell active cytokine IL-7. IL-7-driven enhancement of CTL generation has been reported in vitro. 38 IL-7 can support the growth of specific CTL cultures for prolonged periods of time in the absence of repeated antigenic restimulation. 39 In our experience, tumor cells that have been gene-modified to express IL-7 in conjunction with the CD80 molecule induce a vaccination effect in mice challenged with the breast cancer line TS/A. IL-7-B7 cotransduction into tumor cells proved to be superior to either molecule alone. 33 In analogy to vaccination with cytokine transfected tumor cells, IL-7 transduced DC could provide a high local IL-7 concentration at the putative site of T cell priming. Ideally, DC would directly stimulate those T cells that interact with their antigen-MHC complex. Both genetically engineered tumor cell vaccines and tumor antigen-pulsed DC provide MHC-complexed presentation of tumor antigens together with costimulatory signals. DC-based vaccines might circumvent possible escape mechanisms of tumor cells such as defects or down-regulation of the antigen processing/presentation machinery.
In this article a retrovirus coding for IL-7 has been constructed. We have shown that DC can be retrovirally gene-modified to secrete substantial amounts of IL-7. Although the amount of IL-7 secreted decreases during prolonged culture (data not shown) gene-modified, IL-7 secreting DC would provide a potent stimulus for T cells after reinfusion.
IL-7 secretion was sufficient to augment T cell proliferation in a 5-day MLR and to induce an increased release of TNF-␣. In the single culture wells of MLR, we could clearly correlate the increase in T cell proliferation and in TNF-␣ secretion to the endogenous secretion of IL-7 by the gene-modified DC. DC do not spontaneously express IL-7 receptors on FACS analysis nor does exogenously supplied IL-7 increase the T cell stimulatory capacity of DC, so that an autocrine loop affecting DC function can be excluded.
Using a control retrovirus coding for ␤-galactosidase, transduction efficiency was about 30%. For efficient gene transfer it was essential to start retroviral infection on day 1 or 2 of the cell culture, since proliferative activity decreases rapidly during the culture period. Repeated infection cycles were superior to one single infection. Correlation between repeated retroviral infections and transgene expression level has also been reported by other authors. 40, 41 For clinical applications, gene-modified, IL-7 secreting DC might be of particular value, provided that the modified and retransfused DC are able to home to T cell areas in lymphatic tissues and to prime naive T cells.
In the clinical situation where tumor cells may present antigens without costimulation, possibly inducing specific tolerance, 7 IL-7 secreting antigen-pulsed DC might provide an additional signal to reconstitute immunity. In the case of IL-2, it has been demonstrated that exposure of anergic T cells to IL-2 can restore their antigen responsiveness. 42 Signaling through the common ␥-chain of the IL-2, IL-4 and IL-7 receptor can prevent anergy in T cells that have been stimulated through their antigen receptor but without concomitant accessory costimulation. 43 Moreover, IL-7 has been reported to break tolerance of T cells towards an autoantigen in vitro when added to T cells together with the respective (auto)antigen. 44 Application of IL-7 secreting DC might be a tool to enhance T cell response and avoid the systemic toxicity that can be frequently observed under systemic cytokine treatment.
Vaccination with DC presenting tumor antigens after ex vivo peptide pulsing is a promising approach, recent data suggesting that clinical response to vaccination with idiotype-pulsed autologous DC can be achieved in patients with B cell lymphoma. 45 IL-7 transduction of DC might further amplify antitumor T cell responses. However, before any definitive conclusion about the potential clinical value of IL-7 transduced DC can be drawn, animal models will be necessary to confirm both an elevated stimulatory activity of gene-modified DC and a preserved homing and migration capacity.
Materials and methods
Generation of DC DC were generated as described elsewhere. 23 Briefly, buffy coats from healthy volunteers, which were kindly provided by the plasmapheresis Unit (Charite Hospital, Humboldt University, Berlin, Germany) were prepared by density gradient centrifugation on Ficoll-Hypaque (Seromed, Berlin, Germany). After washing, interphase leukocytes were depleted from B and T cells using immunomagnetic CD2 and CD19 Dynabeads (Dynal, Hamburg, Germany). T and B cell-depleted PBMC were plated in six-well Nunclon plates (Nunc, Naperville, IL, USA) at a density of 1 x 10 6 cells/ml in 2 ml of RPMI 1640 supplemented with 4 mm l-glutamine (Gibco, Eggenstein, Germany), 5 x 10 -5 m 2-mercaptoethanol (Roth, Karlsruhe, Germany), 100 U/ml penicillin/streptomycin (Gibco) and 10% heat-inactivated fetal calf serum (FCS) (Gibco). Culture medium was supplemented with 100 ng/ml human GM-CSF (kindly provided by Sandoz, Nü rnberg, Germany) and 1000 U/ml IL-4 (kindly provided by Schering Plough Research Institute, Kenilworth, NJ, USA). After 6-7 days of culture, nonadherent cells were used for further experiments. This fraction is further referred to as DC fraction.
FACS analysis
Direct immunofluorescence cell staining was performed using the following phycoerythrin (PE)-conjugated mouse monoclonal antibodies (MAb): CD1a-PE (Coulter, Krefeld, Germany); IL-7 receptor (Immunotech, Hamburg, Germany); CD2-PE, CD3-PE, CD4-PE, CD8-PE, CD14-PE, CD16-PE, CD19-PE, CD80-PE, anti-HLA-DR-PE, PE-conjugated isotype control antibody (Becton Dickinson, Mountain View, CA, USA); CD86-PE (Pharmingen, Hamburg, Germany). Indirect immunofluorescence cell staining was performed with antibodies against CD54 (Boehringer Mannheim, Germany), CD40, isotype-matched control MAb (Pharmingen) and PEconjugated rat anti-mouse secondary antibody (Becton Dickinson). On a fluorescence activated cell sorter (FACScan, Becton Dickinson) 10 000 cells were analyzed.
Construction of IL-7 retroviruses
The Hodgkin cell line L591 was used to prepare mRNA and cDNA. For amplification of cDNA containing the whole human IL-7 (hIL-7) coding region, the following primers were used: 5′: CCC GCA GAC CAT GTT CCA TGT TTC T and 3′: GCC ACT CCA TAT TTT TCA GTG TTC. The PCR fragment was directly cloned into pCR II vector (TA Cloning Kit; Invitrogen, Leek, The Netherlands). Thereafter, hIL-7 cDNA was cloned into LXSN vector 46 as an EcoRI fragment. LXSN-hIL-7 contains the human IL-7 gene under the long terminal repeat (LTR) promotor control and a neomycin resistance gene which is controlled by a SV40 promoter. For mock infection, the retroviral construct LXSN, lacking the human IL-7 gene insert, was used. The amphotropic packaging cell line PA 317, which was maintained in Dulbecco's modified Eagle's medium (Gibco) containing 10% FCS, was transfected using the calcium phosphate method (Mammalian Transfection Kit; Stratagene, Heidelberg, Germany). Transfectants were selected by use of 1 mg/ml G 418 (Sigma). The virus titer in helper virus-free supernatants was determined on NIH 3T3 cells.
RT-PCR for neomycin phosphotransferase
Total RNA was extracted from 1 x 10 6 target cells with the RNeasy RNA isolation system (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA was converted into single-strand cDNA using random primers (Gibco) and MMLV reverse transcriptase (Amersham, Cleveland, OH, USA). PCR amplification was performed in a final volume of 50 l with 2.5 U of AmpliTaq DNA polymerase and appropiate reaction mix (Perkin Elmer, Branchburg, NJ, USA) using 0.4 m of the following primers for neomycin phosphotransferase: sense-strand neo 5′-TATTCGGCTATGACTGGGCACAA CAGACAA-3′, antisense-strand neo 5′-ACCGTAAA GCAC GAGGAAGCGGTCAGCCCA-3′, sense-strand human ␤-actin 5′-TGACGGGGTCACCCACACTGTGC CCATCTA-3′ and antisense-strand human ␤-actin 5′-AGTCATAGTCCGCCTAGAAGCATTTGCGGT-3′. Thermocycler conditions were 94°C for 1 min, 69°C for 1 min, and 72°C for 1.5 min over 35 cycles. A 680 base pair (bp) fragment for the neomycin phosphotransferase gene and a 661 bp product for human ␤-actin was amplified. Each reaction (10 l) was run on a 1.5% ethidium bromide stained agarose gel. The identity of the amplified neomycin phosphotransferase gene product was proved by digestion of each product with PstI resulting in two specific fragments of 558 and 122 bp.
CD1a enrichment of the dendritic cell population
In three experiments, immunomagnetic separation of CD1a
+ cells was performed to demonstrate expression of marker mRNA (neomycin phosphotransferase) in a highly purified DC fraction: 1 x 10 7 cells were incubated with CD1a MAb for 30 min at 4°C on day 7. After washing, sheep anti-mouse IgG1 Dynabeads (Dynal) were added to the cells at a cell:bead ratio of 1:5 for 30 min at 4°C. CD1a-enriched cells were recovered with a magnetic device and evaluated for expression of neomycin phosphotransferase mRNA.
Mixed lymphocyte reaction (MLR)
T cells were isolated from PBMC by two consecutive rosetting cycles with 2-aminoethyl-isothiouroniumbromide (AET; Sigma, St Louis, MO, USA)-treated sheep red blood cells as described. 47 The T cell fraction recovered from the pellet after lysis with NH 4
+

Cl
− buffer (pH 7.2) consisted of 85-97% CD2 + cells and 79-95% CD3 + cells and 2-21% CD11b
+ monocytes. Contaminating monocytes were removed by additional plastic adherence. The nonrosetting fraction (non-T cells) was enriched for CD19 + B cells (20-44%) and for CD14 + monocytes (7-40%). The stimulator cell fractions (either DC or non-T cells) were irradiated with 30 Gy. Different numbers of stimulator cells were added to the culture wells containing a fixed amount of T lymphocytes (10 5 per well) so that the final stimulator:responder ratio ranged from 1:10 (10 000 stimulator cells per well) to 1:160 (625 stimulator cells per well). After 4 days of culture, 1 Ci/well Retroviral transduction of dendritic cells IL-7 gene transduction was performed using helper virus-free retroviral supernatant with a virus titer of 2 x 10 6 c.f.u./ml on NIH 3T3 cells. The specific activity of the IL-7 secreted was 5 x 10 6 U/mg. After preparation of PBMC as described above, the T and B cell-depleted fraction was cultured in cytokine medium. One milliliter of viral supernatant was added to 1 x 10 6 target cells in 1.0 ml medium. The cytokine concentration of GM-CSF and IL-4 was adjusted to the final concentrations mentioned above. Twelve hours later, two-thirds of the medium was exchanged. This procedure was repeated on culture days 2, 3 and 5. On day 6, cells were extensively washed and the medium was changed completely. IL-7 production was then measured in the cell cultures by ELISA, starting 24 h later. Cells from the same wells were used for functional experiments. Mock infections were carried out in a similar way. Infection with a control retrovirus coding for ␤-galactosidase was performed in a similar way.
ELISA
Determination of IL-7 and TNF production in culture supernatants and MLR wells was carried out by ELISA (Quantikine Human IL-7, Quantikine HS Human IL-7 and Quantikine Human TNF-␣; R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
